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A b s t r a c t
Trimetazidine is an anti-ischaemic drug used for angina pectoris treatment.
Recently, it has been shown that trimetazidine protects against hepatic ischaemia
reperfusion injury. Several hypotheses have been proposed to explain the exact
hepatoprotective mechanisms but they still remain unclear. This review assesses
the possible mechanisms responsible for the increase of the liver’s tolerance
against ischaemia-reperfusion injury with special emphasis on: (1) the prevention
of oxidative stress and protection of mitochondrial function; (2) the generation
of vasoactive mediators such as nitric oxide and endothelins; and finally (3) the
preservation of liver energy metabolism.
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Introduction
Ischaemia-reperfusion injury is an inherent phenomenon that results
following major liver surgery procedures such as hepatic resections and
hepatic transplantation. Both clinical situations lead to the interruption of
hepatic blood flow to the organ (ischaemia) followed by its subsequent
restoration (reperfusion), thus originating severe damage known as
ischaemia-reperfusion injury (IRI) [1, 2]. It is well known that IRI impacts
directly on liver morbidity and mortality post surgery, especially when
steatosis is present [3].
During ischaemia, cellular damage is induced as a consequence of
cellular adenosine triphosphate (ATP) depletion and lactate accumulation,
this being concomitant with derangements in calcium homeostasis [4].
After reperfusion, the ischaemic injury is aggravated by the generation of
toxic reactive oxygen species (ROS) as a consequence of blood flow
restoration. This is accompanied by the subsequent generation of
inflammatory mediators and neutrophil accumulation which contribute to
the progress of hepatic lesion [4]. Consequently, the prevention of liver
vulnerability against ischaemia-reperfusion damage is determinant to
preserve the organ function in experimental and clinical settings.
Trimetazidine or (1-2(2,3,4-trimeoxibenzyl)-piperazine) (TMZ) is a clinically
effective anti-ischaemic drug that is currently used in some European
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countries to treat angina pectoris [5, 6]. Its anti-
ischaemic property is thought to be due to its ability
to limit ATP depletion and intracellular acidosis [7].
Also, TMZ is able to reduce the generation of toxic
free radicals during reperfusion [7]. Recently, there
is increasing evidence that the cardioprotective
effects exerted by TMZ can be extrapolated to the
liver. This review assesses the possible protective
mechanisms of TMZ against warm and cold liver
ischaemia-reperfusion injury, especially in the
presence of steatosis.
Protective mechanisms of TMZ against liver IRI
TMZ and its derivatives protect the liver against
warm and cold ischaemia reperfusion injury [8-14].
These beneficial effects were initially associated
with its antioxidant effects but the mechanisms
responsible for this hepatoprotection seem to be
more complex, and they include the involvement of
freely diffusible molecules/radicals, such as nitric
oxide (NO) and adenosine, which can act in
autocrine and/or paracrine fashion as triggers to
induce more protection and activate different
transduction cell signalling factors, such as hypoxic
inducible factor (HIF) [15].
Oxidative stress and mitochondrial function
Reactive oxygen species (ROS) production
occurring during the ischaemia-reperfusion process
seems to be a major determinant of tissue injury.
These ROS are generated from both intracellular
and extracellular sources [16] but liver mitochondria
appears to be the most important [17]. TMZ reduced
liver oxidative stress under warm ischaemia-
reperfusion [8], this being well correlated with the
preservation of mitochondrial function when TMZ
was administered at the optimal dosage of 
10 mg/kg/day [18]. Recent studies revealed that
preservation of mitochondrial function exerted by
TMZ in liver appears to be due to the closure of the
mitochondrial permeability transition pore [10]. In
line with this, we have recently demonstrated that
TMZ addition to UW solution effectively preserved
normal and steatotic livers against cold ischaemia-
reperfusion injury [13, 14].
Nitric oxide
Nitric oxide (NO) is an important protective
molecule due to its vasodilator and antioxidant
properties. NO exerts its beneficial effects on
oxidative stress in fatty livers undergoing ischaemia-
reperfusion. Data showing the implication of NO in
the cardioprotective effects of TMZ are scarce [19].
In this line, our recent investigations on fatty liver
preservation point to the direct involvement of NO
in the hepatoprotection induced by TMZ against
ischaemia-reperfusion injury. We have demonstrated
that this transient generation of NO was produced
as a consequence of activation of the constitutive
nitric oxide synthase (cNOS) when steatotic livers
were preserved in UW solution enriched with TMZ
[14]. Thus, the NO formed would contribute to
ameliorating the oxygenation of hepatic tissue [20]
and to preventing the altered microcirculation in fatty
livers due to fat accumulation in liver sinusoids [21].
Additional NO benefits could also be associated
with its inhibitory action on liver endothelins (ETs)
[22]. Endothelins are potent vasoconstrictor peptides
generated during earlier stages of liver reperfusion
which are responsible for the reduction of sinusoid
diameter with the subsequent induction of
microcirculatory derangements, especially when
steatosis is present [21]. These increased NO levels
induced by TMZ could be associated with increases
in adenosine release to the extracellular space as 
a consequence of the activation of specific adenosine
receptors, as similarly occurred in liver ischaemic
preconditioning [23] (Figure 1). In this sense, the
increased adenosine plasma levels determined in
treated TMZ patients affected by angina pectoris [24]
seem to confirm this hypothesis. The administration
of specific adenosine receptor antagonists in
experimental models of warm ischaemia-reperfusion
could clarify which kind of adenosine receptors are
directly involved in the protective mechanisms
induced by TMZ.
Energy metabolism
It is clear that TMZ improves energy recovery in
different ischaemic models [9, 13, 14]. Recent studies
carried out by our group evidenced that these
beneficial effects are mediated by the activation of
adenosine monophosphate protein kinase (AMPK)
[14], a primary sensor of changes in cell energy during
ischaemia. Fatty livers conserved in UW solution
enriched with TMZ showed effective prevention of
energy metabolism breakdown which correlated with
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Figure 1. Proposed mechanisms responsible for
hepatoprotection induced by TMZ against liver
ischaemia-reperfusion injury
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benefits in hepatic injury and liver function [14],
respectively. In these conditions, the presence of
AMPK inhibitors in UW solution abolished all the 
NO-dependent benefits of TMZ [14].
Signal transduction
Hypoxia-inducible factor (HIF) generated during
hypoxic injury has recently been implicated in the
regulation of mitochondrial signalling, hypoxic cell
death and recovery from IRI [15]. Overexpression of
HIF was induced in TMZ treated pig kidneys
subjected to ischaemia-reperfusion [25]. These
interesting results justify addressing further
investigations to explore the potential role of HIF in
the hepatoprotective mechanisms induced by TMZ
against warm and cold ischaemia-reperfusion injury.
In conclusions TMZ protected the liver against
warm and cold ischaemia-reperfusion injury and
ameliorated liver function in steatotic and non-
steatotic livers. Further investigations will be needed
to elucidate the exact hepatoprotective mechanisms
and evaluate whether TMZ treatments could be
promising in major liver surgery procedures such as
hepatectomies and orthotopic liver transplantation.
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